Kyoto, Japan — Sometimes too much of a good thing is not good at all. Inhibiting the function of the PD-1 protein, which blocks immune function, has shown high therapeutic efficacy in cancer immunotherapy.
Credit: KyotoU Global Comms/Chie Naruse
Kyoto, Japan — Sometimes too much of a good thing is not good at all. Inhibiting the function of the PD-1 protein, which blocks immune function, has shown high therapeutic efficacy in cancer immunotherapy.
However, when this function is inhibited for an extended period of time, autoimmune diseases may develop.
Now, researchers at Kyoto University have developed a cancer therapy model in which existing medication can be used to transiently degrade and reduce the protein responsible for programmed cell death.
“We constructed a cancer therapy model in which endogenous PD-1 on immune cells in mice can be degraded for only a necessary period of time,” says lead author Chie Naruse.
Her team utilizes the small-molecule-assisted shutoff — or SMASh — degron system in both cultured cells and mice in vivo after introducing the medically-approved protease inhibitors asunaprevir and grazoprevir.
SMASh tags are used as markers for proteolysis in the degron system, where they are fused to the PD-1 protein. This approach is effective in demonstrating the reduction of PD-1 in specific T cells after drug administration.
“Cancer cell growth was also suppressed in wild-type mice in which immune cells were replaced with those from knock-in mice,” the author adds.
The method, however, may require some tweaking. Some older knock-in mice were observed to develop mild autoimmune diseases without the introduction of either inhibitor.
Naruse concludes, “We are now working on an improved system in which PD-1 degradation does not occur without drug administration, possibly leading the way to a simpler treatment for cancer.”
###
The paper “A degron system targeting endogenous PD-1 inhibits the growth of tumor cells in mice” appeared on 17 June 2022 in NAR Cancer, with doi: 10.1093/narcan/zcac019
About Kyoto University
Kyoto University is one of Japan and Asia’s premier research institutions, founded in 1897 and responsible for producing numerous Nobel laureates and winners of other prestigious international prizes. A broad curriculum across the arts and sciences at both undergraduate and graduate levels is complemented by numerous research centers, as well as facilities and offices around Japan and the world. For more information please see: http://www.kyoto-u.ac.jp/en
Journal
NAR Cancer
DOI
10.1093/narcan/zcac019
Method of Research
Experimental study
Subject of Research
Animals
Article Title
A degron system targeting endogenous PD-1 inhibits the growth of tumor cells in mice
Article Publication Date
17-Jun-2022
COI Statement
The author declares no conflict of interest.
